Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Not Applicable

Completed

• Conditions: Infectious Keratitis

• Registration Number: NCT01739673
• Lead Sponsor: Cxlusa

Brief Summary

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2012-11-27
• Study First Submitted QC: 2012-11-30
• Study First Posted: 2012-12-03
• Primary Completion: 2014-07
• Study Completion: 2014-07
• Status Verified: 2015-08
• Last Update Submitted: 2018-09-24
• Last Update Posted: 2018-09-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

1. Subjects must be 18 years of age or older.
2. Ability to provide written informed consent.
3. Likely to complete all study visits.
4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion Criteria

1. A corneal perforation.
2. Descemetocele.
3. Pregnancy or breastfeeding.
4. Active Herpes corneal disease.
5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Resolution of Signs and Symptoms of Infectious Keratitis	Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks

Trial Locations

Locations (6)

Schwartz Laser Eye Center; 🇺🇸 Scottsdale, Arizona, United States

Davidorf Eye Group; 🇺🇸 West Hills, California, United States

Corneal Consultants of Colorado, PC; 🇺🇸 Littleton, Colorado, United States

Center for Excellence in Eye Care; 🇺🇸 Miami, Florida, United States

Minnesota Eye Consultants; 🇺🇸 Minneapolis, Minnesota, United States

Ophthalmology Associates; 🇺🇸 Saint Louis, Missouri, United States